SCHEMBL854419

SCHEMBL854419

CC(C)(C)NC(=O)OC1CCNCC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM3 P20309 2/20 0.42
EPHX1 P07099 3/20 0.37
DPP4 P27487 2/20 0.35
CHRM2 P08172 1/20 0.34
CHRM1 P11229 1/20 0.34
CCNE1 P24864 6/20 0.34
CDK2 P24941 6/20 0.34
TPSAB1 Q15661 1/20 0.34
TPSD1 Q9BZJ3 1/20 0.34
TPSG1 Q9NRR2 1/20 0.34
GBA1 P04062 1/20 0.33
GABRP O00591 1/20 0.33
GABRD O14764 1/20 0.33
GABRA1 P14867 1/20 0.33
TSHR P16473 1/20 0.33
GABRB1 P18505 1/20 0.33
GABRG2 P18507 1/20 0.33
GABRB3 P28472 1/20 0.33
GABRA5 P31644 1/20 0.33
GABRA3 P34903 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL27795195 0.98 CHRM3 (0.41) CHRM3EPHX1DPP4CHRM2CHRM1
Ammonia Solution, Strong SCHEMBL28789148 0.98 CHRM3 (0.41) CHRM3EPHX1DPP4CHRM2CHRM1
Methane SCHEMBL27517655 0.98 CHRM3 (0.41) CHRM3EPHX1DPP4CHRM2CHRM1
Hydrochloric Acid SCHEMBL27564439 0.98 CHRM3 (0.41) CHRM3EPHX1DPP4CHRM2CHRM1
SCHEMBL16505644 0.93 EPHX1 (0.40) CHRM3EPHX1DPP4CHRM2CHRM1
SCHEMBL1441784 0.89 CHRM3 (0.35) CHRM3DPP4CCNE1CDK2SMN1; SMN2
SCHEMBL954529 0.89 CHRM3 (0.35) CHRM3DPP4CCNE1CDK2SMN1; SMN2
SCHEMBL954528 0.89 CHRM3 (0.35) CHRM3DPP4CCNE1CDK2SMN1; SMN2
Methane SCHEMBL27926432 0.88 CHRM3 (0.34) CHRM3DPP4CCNE1CDK2GSK3B
Hydrochloric Acid SCHEMBL28057619 0.88 DPP4 (0.35) CHRM3DPP4CCNE1CDK2GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 300 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112441772-A Preparation process of ceramic friction material for automobile brake pad 安徽瑞荣汽车零部件有限公司 2021-03-05 CN claimed
CN-107382984-B Preparation method of medicine for treating leukemia 扬州市三药制药有限公司 2020-07-10 CN claimed
CN-109678849-A A kind of preparation method of anticancer drug 北京悦康科创医药科技股份有限公司 2019-04-26 CN claimed
CN-107382983-A A kind of synthetic method for treating leukemia medicament 扬州市三药制药有限公司 2017-11-24 CN claimed
CN-107382984-A A kind of preparation method for treating leukemia medicament 扬州市三药制药有限公司 2017-11-24 CN claimed
WO-2024107434-A1 AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF Samsara Therapeutics Inc. (US) 2024-05-23 WO disclosed
US-20240101552-A1 CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2024-03-28 US disclosed
EP-4342882-A1 BENZAMIDE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER CONTAINING SAME AS ACTIVE INGREDIENT HK inno.N Corporation (KR) 2024-03-27 EP disclosed
WO-2024044744-A2 PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) 2024-02-29 WO disclosed
WO-2024044751-A2 PEROXIREDOXIN 3 INHIBITORS AND METHODS OF USE FOR TREATING CANCER WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) 2024-02-29 WO disclosed
US-20230303512-A1 MODULATORS OF MYB-MEDIATED TRANSCRIPTION AND USES THEREOF MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2023-09-28 US disclosed
EP-4215526-A1 CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF Shanghai Pharmaceuticals Holding Co., Ltd. (CN) 2023-07-26 EP disclosed
CN-1777612-A New piperidinylamino-thieno[2,3-d] pyrimidine compounds PREDIX PHARMACEUTICALS HOLDING (US) 2006-05-24 CN disclosed
CN-1764661-A Benzenesulfonamide derivatives, process for their preparation and their use for the treatment of pain FOURNIER LAB SA (FR) 2006-04-26 CN disclosed
US-20050250792-A1 Substituted piperidine compounds useful as modulators of chemokine receptor activity MERRILL LYNCH CAPITAL, A DIVISION OF MERRILL LYNCH BUSINESS FINANCIAL SERVICES, INC. AS ADMINISTRATIVE AGENT 2005-11-10 US disclosed
CN-1665785-A 2-cyano-4-fluoropyrrolidine derivative or its salt YAMANOUCHI PHARMA CO LTD (JP) 2005-09-07 CN disclosed
CN-1642906-A Novel arylamidine derivative or salt thereof TOYAMA CHEMICAL CO LTD (JP) 2005-07-20 CN disclosed
CN-1189467-C Pharmaceutically active sulfonamide derivatives APPLIED RES SYSTEM ARS HOLDING (AN) 2005-02-16 CN disclosed
CN-1498205-A Aryl and biaryl compounds having MCH modulatory activity �����Ƥ�� 2004-05-19 CN disclosed
CN-1377347-A Pharmaceutically active sulfonamide derivatives APPLIED RESEARCH SYSTEMS (NL) 2002-10-30 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240101552-A1 CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF LANCL2, CBS, LCP2 CHRM3 4752/4885EPHX1 4188/4885DPP4 1505/4885
US-20230303512-A1 MODULATORS OF MYB-MEDIATED TRANSCRIPTION AND USES THEREOF MYB, MYBBP1A, MYCBP CHRM3 4372/4885EPHX1 4259/4885DPP4 4550/4885
US-20050250792-A1 Substituted piperidine compounds useful as modulators of chemokine receptor activity CXCR4, CXCR1, CXCR3 CHRM3 78/4885EPHX1 678/4885DPP4 1232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.